Antipyretic and analgesic methods of using optically pure R-etod

Details Antipyretic and analgesic methods of using optically pure R-etod Antipyretic and analgesic methods of using optically pure R-etod

1995-01-04

1996-10-01

Cintins, Marianne M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 3140

Patent

active

055611516

ABSTRACT:
Methods are disclosed utilizing optically pure R(-) etodolac for the treatment of pain, including but not limited to pain associated with toothaches, headaches, sprains, joint pain and surgical pain, for example dental pain and ophthalmic pain, while substantially reducing adverse effects which are associated with the administration of the racemic mixture of etodolac. The optically pure R(-) etodolac is also useful in treating pyrexia while substantially reducing the adverse effects associated with the administration of the racemic mixture of etodolac.

REFERENCES:
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3896145 (1975-07-01), Berger et al.
patent: 3904682 (1975-09-01), Fried et al.
patent: 4501899 (1985-02-01), Abraham et al.
patent: 4515961 (1985-05-01), Demerson et al.
patent: 4520203 (1985-05-01), Abraham et al.
patent: 4927854 (1990-05-01), Sunshine et al.
patent: 4962124 (1990-10-01), Sunshine et al.
patent: 4983765 (1991-01-01), Lukas et al.
Brune et al., "Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition", Experientia 47:257-261 (1991).
Brocks and Jamali, "The pharmacokinetics of etodolac enantiomers in the rat", Drug Metabolism and Disposition 18(4): 471-475 (1990).
Geisslinger et al., "Pharmacokinetics of S(+)-and R(-)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis", Eur. J. Clin. Phar. 38(5): 493-497 (1990).
Knihinicki et al., "Stereoselective disposition of ibuprofen and flurbiprofen in rats", Chirality 2: 134-140 (1990).
Muller et al., "Pharmacological aspects of chiral nonsteroidal anti-inflammatory drugs", Fundam. Clin. Pharmacol. 4: 617-634 (1990).
Murray and Brater, "Nonsteroidal anti-inflammatory drugs", Clin. Pharm. 6(2): 365-397 (1990).
Williams, "Enantiomers in arthritic disorders", Pharmac. Ther. 46: 273-295 (1990).
Jamali et al., "Enantioselective aspects of drug action and disposition: Therapeutic pitfalls", J. Pharm. Sci. 78(9): 696-715 (1989).
Caldwell et al., "The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences", Biochemical Pharmacology 37(1): 105-114 (1988).
Jamali, "Research methodology in NSAID monitoring: Plasma concentrations of chiral drugs", J. Rheum. 15: 71-74 (1988).
Jamali et al., "Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans", J. Pharm. Sci. 77(11): 963-966 (1988).
Jamali, "Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs", Eur. J. Drug Met. Pharm. 13(1): 1-9 (1988).
Williams and Day, "The contribution of enantiomers to variability in response to anti-inflammatory drugs", Anti-Rheumatic Drugs AAS 24: 76-84 (1988).
Humber, "Etodolac: The chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid", Medicinal Research Reviews 7(1): 1-28 (1987).
Yamaguchi et al., "The inhibitory activities of 480156-S and its related compounds on prostaglandin synthetase", Folia pharmacol. japon. 90: 295-302 (1987) (contains English abstract).
Humber et al., "Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid): A potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer", J. Med. Chem. 29: 871-874 (1986).
Meffin et al., "Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. I. 2-phenylpropionic acid disposition", J. Pharm. Exp. Therm. 238(1): 280-287 (1986).
Singh et al., "Stereoselective gas chromatographic analysis of etodolac enantiomers in human plasma and urine", J. Chromat. 382: 331-337 (1986).
Singh et al., "Pharmacokinetics of the enantiomers of tiaprofenic acid in humans", J. Pharm. Sci. 75(5): 439-442 (1986).
Williams and Day, "Stereoselective disposition--basis for variability in response to NSAID's", Non-steroidal Anti-Inflammatory Drugs 17: 119-126 (1985).
Scrip's New Product Review No. 4 Etodolac, PJB Publications Ltd. (1985).
Hutt and Caldwell, "The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid non-steroidal anti-inflammatory drugs", Clinical Pharmacokinetics 9: 371-373 (1984).
Tamassia et al., "Pharmacokinetics of the enantiomers of indoprofen in man", Int. J. Clin. Pharm. Res. IV(3): 223-230 (1984).
Demerson et al., "Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers", J. Med. Chem. 26: 1778-1780 (1983).
Hutt and Caldwell, "The metabolic chiral inversion of 2-arylpropionic acids--a novel route with pharmacological consequences", J. Pharm. Pharmacol. 35: 693-704 (1983).
Goto et al., "Separation and determination of naproxen enantiomers in serum by high-performance liquid chromatography", J. Chromat. 239: 559-564 (1982).
Kemmerer et al., "Stereospecific assay and stereospecific disposition of racemic carprofen in rats", J. Pharm. Sci. 68(10): 1274-1280 (1979).
Inoue et al., Chemical Abstracts, vol. 114, No. 25, abstract No. 240197k, 1991.
Brocks et al., Biological Abstracts, vol. 93, No. 4, abstract # 44336, 1991 .

Affiliated with

Also associated with

Rating

Antipyretic and analgesic methods of using optically pure R-etod does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antipyretic and analgesic methods of using optically pure R-etod, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antipyretic and analgesic methods of using optically pure R-etod will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1502198